BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Vimgreen Pharmaceuticals readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Vimgreen Pharmaceuticals's drugs 
 run\, from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07725562-1735@assetmemo.bio
DTSTAMP:20261121T005707Z
DTSTART;VALUE=DATE:20271001
DTEND;VALUE=DATE:20271002
SUMMARY:VG081821AC: Phase 2/3 readout est. (NCT07725562)
DESCRIPTION:VG081821AC\, phase 2/3\, Parkinson's Disease.\nStudy: VG081821A
 C Tablets for Early to Mid-stage Parkinson's Disease\nEstimated primary co
 mpletion: 1 October 2027. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/vg081821ac#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT07725562
URL:https://assetmemo.bio/drug/vg081821ac#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
